Business Description
Amylyx Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US03237H1014
Total Employee Number:
136Compare
Compare
Traded in other countries / regions
AMLX.USA Index Membership
Russell 2000Russell 3000Russell 2000Russell 3000 IPO Date
2022-01-07Description
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 49.68 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22.2 | |||||
3-Year EPS without NRI Growth Rate | 23.3 | |||||
3-Year FCF Growth Rate | 25.2 | |||||
3-Year Book Growth Rate | -18.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.33 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.2 | |||||
9-Day RSI | 58.1 | |||||
14-Day RSI | 60.39 | |||||
3-1 Month Momentum % | -17.73 | |||||
6-1 Month Momentum % | 10.24 | |||||
12-1 Month Momentum % | 82.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 17.85 | |||||
Quick Ratio | 17.85 | |||||
Cash Ratio | 17.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18.2 | |||||
Shareholder Yield % | -0.18 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -58.65 | |||||
ROA % | -53.49 | |||||
ROIC % | -1025.7 | |||||
3-Year ROIIC % | -762.34 | |||||
ROC (Joel Greenblatt) % | -3212.6 | |||||
ROCE % | -61.28 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 7.22 | |||||
Price-to-Tangible-Book | 7.22 | |||||
EV-to-EBIT | -10.68 | |||||
EV-to-EBITDA | -10.72 | |||||
EV-to-Forward-Revenue | 101.41 | |||||
EV-to-FCF | -14.12 | |||||
| Price-to-Net-Current-Asset-Value | 7.47 | |||||
| Price-to-Net-Cash | 7.59 | |||||
Earnings Yield (Greenblatt) % | -9.36 | |||||
FCF Yield % | -6.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AMLX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amylyx Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.5 | ||
| Beta | 0.8269 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 0.83 | ||
| Volatility % | 61.83 | ||
| 14-Day RSI | 60.39 | ||
| 14-Day ATR ($) | 0.987504 | ||
| 20-Day SMA ($) | 16.8795 | ||
| 12-1 Month Momentum % | 82.14 | ||
| 52-Week Range ($) | 7.21 - 19.15 | ||
| Shares Outstanding (Mil) | 111.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amylyx Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amylyx Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 117 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 116 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 10:40 | 13.55 (+2.26%) | ||
| General meeting for 2026 | 2026-06-04 09:00 | 13.20 (-0.75%) | ||
| Guidance call for 2026 | 2026-05-13 13:40 | 14.44 (-2.50%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 16.06 (-2.73%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 16.06 (-2.73%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-15 08:45 | 16.92 (+1.93%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 08:00 | 14.31 (+2.00%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 11:10 | 15.30 (+2.00%) |
Show
Entries
Amylyx Pharmaceuticals Inc Frequently Asked Questions
What is Amylyx Pharmaceuticals Inc(AMLX)'s stock price today?
The current price of AMLX is $17.77. The 52 week high of AMLX is $19.15 and 52 week low is $7.21.
When is next earnings date of Amylyx Pharmaceuticals Inc(AMLX)?
The next earnings date of Amylyx Pharmaceuticals Inc(AMLX) is 2026-11-06 Est..
Does Amylyx Pharmaceuticals Inc(AMLX) pay dividends? If so, how much?
Amylyx Pharmaceuticals Inc(AMLX) does not pay dividend.
Guru Commentaries on NAS:AMLX
No articles.
Press Release
Articles on Amylyx Pharmaceuticals Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers